-
Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 2.2 modified drug, HY-2003. This drug is designed to improve moderate to severe contour protrusion caused by subcutaneous fat accumulation…
-
J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry
•
Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter another potential competitor in the Chinese market. CSPC Pharmaceutical Group Ltd (HKG: 1093), a local firm, has recently announced that the National Medical Products Administration (NMPA) has accepted its market filing for review, marking a…
-
AstraZeneca’s ALXN1850 (Efzimfotase Alfa) Selected for China’s Rare Disease Care Plan
•
The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s (AZ, NASDAQ: AZN) ALXN1850, known as efzimfotase alfa, in the patient-centered rare disease drug development pilot program, referred to as the Care Plan. This move signifies a significant step forward in the global efforts to…
-
Amgen’s MariTide Showcases Significant Weight Loss in Phase II Study
•
US biotechnology company Amgen (NASDAQ: AMGN) has announced positive outcomes from the double-blind, dose-ranging Phase II study of MariTide (maridebart cafraglutide), formerly known as AMG 133, at 52 weeks. This investigational antibody peptide conjugate, administered subcutaneously on a monthly or less frequent basis, has demonstrated significant potential in obesity treatment.…
-
VectorBuilder and Zhejiang Dapu Biotechnology Form Partnership to Advance Biotech Innovation
•
China-based gene delivery technology developer VectorBuilder has entered into a partnership with Zhejiang Dapu Biotechnology Co., Ltd, a specialist in droplet microfluidics and molecular diagnostics. The collaboration aims to integrate the respective technology advantages and platform resources of both companies to overcome technological bottlenecks in life sciences and innovative biopharmaceutical…
-
Roche’s SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC
•
Swiss pharmaceutical giant Roche (SWX: ROG) has reported an update on the phase III SKYSCRAPER-01 study, which evaluated the combination of tiragolumab with Tecentriq (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC). SKYSCRAPER-01 Study Details and ResultsThe global, randomized, double-blind…
-
Roche to Acquire Poseida Therapeutics in a USD 1.5 Billion Deal
•
US-based clinical-stage biopharmaceutical company, Poseida Therapeutics (NASDAQ: PSTX), which specializes in donor-derived CAR-T cell therapies, has announced a definitive merger agreement with Roche (SWX: ROG). The deal, valued at a total equity value of USD 1.5 billion, is anticipated to close in the first quarter of 2025. Expanding Allogeneic Cell…
-
Zymeworks and Jazz Pharmaceuticals’ Ziihera Gets Green Light for HER2+ BTC Treatment
•
Partners Zymeworks Inc. (NASDAQ: ZYME) and Jazz Pharmaceuticals, Inc. have received accelerated approval from the US Food and Drug Administration (FDA) for Ziihera (zanidatamab), a treatment for adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). This marks a significant advancement in the treatment options for…
-
Lakeside Holding’s Hupan Pharmaceutical Partners with Sinopharm Group Hubei for Supply Chain Services
•
US-based supply chain solution provider Lakeside Holding Limited (NASDAQ: LSH), which specializes in the Asian market, has announced a strategic partnership agreement between its recently acquired Hupan Pharmaceutical (Hubei) Co., Ltd. and Sinopharm Group Hubei Co., Ltd., a subsidiary of China’s Sinopharm Group Co., Ltd (HKG: 1099). The financial details…
-
NHSA to Announce NRDL Adjustment Results at November 28th Press Conference
•
The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price bidding for the National Reimbursement Drug List (NRDL) adjustment at a press conference scheduled for 10:00 am on November 28th. This event marks a significant moment in the healthcare sector as it will disclose the…
-
NMPA and Local Governments Streamline Drug Approval Processes in China
•
The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for optimizing the review and approval procedures of supplementary drug applications, a program introduced in February this year. The initiative aims to enhance the efficiency of drug application reviews and has designated Beijing, Tianjin, Hebei province,…
-
Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline
•
Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed Series B financing round, raising USD135 million. The proceeds from this round will be utilized to accelerate the development of its first-in-class ADC pipeline, which includes the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05,…
-
Abbott Laboratories Expands Structural Heart Portfolio with TAVI Balloon-Expandable System
•
US-based Abbott Laboratories (NYSE: ABT) has announced the successful application of its transcatheter aortic valve implantation (TAVI) balloon-expandable system in treating the first patient with symptomatic severe aortic stenosis. This milestone marks a significant step forward in the company’s efforts to provide advanced heart valve therapies. Pioneering Software-Guided TAVI SystemThe…
-
Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH
•
US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced positive interim analysis results from the pivotal Phase III ZENITH study for its activin signaling inhibitor, Winrevair (sotatercept-csrk). The study focused on the efficacy and safety of sotatercept in treating adults with pulmonary arterial hypertension (PAH) who are in…
-
Boston Scientific Corporation to Acquire Intera Oncology Inc., Expanding Cancer Treatment Portfolio
•
US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has announced a definitive acquisition agreement with fellow US firm Intera Oncology Inc., a company specializing in devices for the treatment of colorectal cancer and cholangiocarcinoma. The transaction is anticipated to be completed in the first half of 2025, marking a…
-
Nasal-Phyto Pharmaceutical Receives FDA Clearance for First-Ever Olfactory Drug-Device Combo
•
China-based Nasal-Phyto Pharmaceutical Technology Group Co., Ltd has announced receiving clinical clearance from the US Food and Drug Administration (FDA) for its NPRD003, the world’s first precision olfactory area constant flow drip drug-device combination product. The product is indicated for the treatment of cerebral vasospasm secondary to subarachnoid hemorrhage (SAH).…
-
GSK’s Blenrep BLA for Multiple Myeloma Treatments Accepted by FDA for Review
•
UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep (belantamab mafodotin). GSK is seeking approval for the drug in combination with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex…
-
Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939
•
China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its potential best-in-class ENPP1 inhibitor, ISM5939, in solid tumors. ISM5939: A Promising ENPP1 InhibitorISM5939 targets ENPP1, an external nucleotide pyrophosphatase…
-
SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024
•
SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced the presentation of new data from the Phase I clinical study of its pioneering therapy, SCG101, at the 2024 AASLD Liver Meeting. SCG101 is an autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T)…
-
Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the enrollment of the first patient in the Phase I study for its 20-valent pneumococcal polysaccharide conjugate vaccine. This vaccine is designed to prevent infectious diseases caused by 20 pneumococcal serotypes, targeting infants and children aged between 2 months…
